WS #3043

The data dump reinforces escalating geopolitical tensions in the Middle East, with the Strait of Hormuz remaining closed and Iran demanding crew and cargo details for passage, corroborated by Bloomberg and multiple social media reports. This sustains severe oil supply disruptions, pushing prices near $100, and BlackRock's CEO warns of a global recession if oil hits $150, adding to bearish macroeconomic sentiment. Concurrently, Ukrainian drone attacks on Russian oil infrastructure, including a key export terminal near Saint Petersburg, continue to hamper Russia's war funding, further pressuring energy supplies. However, a nascent diplomatic counter-narrative emerges with Pakistan delivering a US proposal for talks to end the Iran war, reported by Reuters and Bloomberg, though venue details are undecided, offering potential relief if progress materializes. Corporate developments include PDD Holdings missing Q4 earnings estimates, with adjusted EPS of $2.53 versus $3.21 expected, likely bearish for PDD and Chinese tech sentiment. In US policy, a bipartisan Senate deal to cap insulin costs at $35, reported by Semafor and multiple sources, is bearish for pharmaceutical giants like Eli Lilly (LLY) and Novo Nordisk (NVO). Analyst actions show bullish sentiment on specific healthcare stocks (Incyte, Avalo Therapeutics, Kestra Medical Techs), but these are overshadowed by macro risks. Market indices show global gains, with Indian markets (Nifty, Sensex) up strongly, suggesting regional divergence, while oil prices are down 5.23% to $87.52 in this window, possibly reflecting short-term volatility or profit-taking amid the broader supply crisis.